CSPC Pharmaceutical Group Limited — Capital/Financing Update 2021

Mar 9, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [62 x 90] intentionally omitted <==

CSPC PharmaCeutiCal GrouP limited 石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VoluNtarY aNNouNCemeNt

ProduCt liCeNSiNG aNd CommerCialiZatioN aGreemeNt

The board of directors (the “ Board ”) of CSPC Pharmaceutical Group Limited (the “ Company ” and together with its subsidiaries, the “ Group ”) is pleased to announce that CSPC Pharmaceutical (Shanghai) Company Ltd.（石藥（上海）有限公司）(“ CSPC Shanghai ”), a wholly-owned subsidiary of the Company, has entered into a product licensing and commercialization agreement (the “ agreement ”) with Beta Pharma (Shanghai) Company Limited（上海倍而達藥業有限公司） (“ Beta Pharma ”) in relation to the exclusive product licensing and commercialization of BPI-7711 Capsules, a third generation irreversible EGFR-TKI for the treatment of non-small cell lung cancer.

Pursuant to the Agreement, CSPC Shanghai shall be granted the exclusive rights for commercialization of BPI-7711 Capsules in the People’s Republic of China (including Hong Kong Special Administrative Region and Macau Special Administrative Region but excluding Taiwan) and shall have the right of first negotiation on licensing of commercialization of BPI-1178 Capsules (a CDK 4/6 inhibitor).

At the same time, the Group has agreed to subscribe for shares in the Beta Pharma group, with the initial subscription at a consideration of RMB200 million, which is subject to the fulfillment of certain conditions precedent.

The new drug application for BPI-7711 Capsules will be submitted in China soon.

The Board believes that the inclusion of such product will further enrich the Group’s oncology products portfolio. Leveraging on its strong capability in sales and marketing, the Group will accelerate the commercialization of such product to meet the urgent clinical needs of patients in China.

— 1 —

By Order of the Board CSPC Pharmaceutical Group limited Cai dongchen

Chairman

Hong Kong, 9 March 2021

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.

• For identification purpose only.

— 2 —